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Potential impact of the new WHO guidelines on the power in the HPTN071-
PopART trial - Mathematical modelling as submitted to the HPTN 071 
(PopART) DSMB not peer-reviewed by PLOS Medicine 
 
Executive summary 
In June 2013, the WHO released new guidelines on the use of antiretroviral therapy 
(ART) for treating and preventing HIV infection, recommending broadening the 
spectrum of individuals eligible for initiation of ART [1]. The adoption by Zambia and 
South Africa of these new WHO guidelines would affect the HPTN-071 (popART) trial, in 
which individuals in arm C (standard of care) and B (universal testing but treatment 
according to national guidelines) are treated according to the national guidelines.  
 
We extended the mathematical model developed to assist the trial design in order to 
assess the potential impact of the changes in national guidelines on the power of the trial 
to detect differences in 3-year cumulative HIV incidence between the different arms. The 
model is an extension of that described in a manuscript submitted for publication in PLoS 
one which is attached to the current document. New findings are presented in the same 
format for comparison.  
 
We explored 5 scenarios in which the date of adoption of the new guidelines was varied 
as well as the proportion of the HIV positive individuals who would become eligible 
according to the new guidelines. If targets are reached, our model predicts that the HIV 
incidence over 3 years would be reduced by 61% to 56% in Zambia and 62% to 58% in 
South Africa in arm A and 25% to 37% in Zambia and 26% to 39% in South Africa in arm 
B, compared to arm C, depending on assumptions about the time of adoption the new 
guidelines and the expected size of the population affected by them. The earlier the new 
guidelines are adopted, and the more HIV positive individuals they affect, the larger the 
power of detecting a difference in HIV incidence over 3 years between arms B and C, but 
the smaller the power to detect a difference between arms A and B or A and C. However, 
even in the most extreme scenario, the power of detecting a difference between arms A 
and C would remain above 99%, and the power of detecting a difference between arms 
A and B would remain above 60%, the power of detecting a difference between arms B 
and C increasing to at least 75%.  
 
Importantly, we found that the variability in the predicted reduction in HIV incidence in 
the intervention arms associated with uncertainty in the trial uptake and potential 
changes in behaviors at the community level was much larger than that associated with 
uncertainty in the date of adoption and impact of the new guidelines in country.  
 
In summary, our model indicates that although the adoption of the new WHO guidelines 
in country will affect the reduction in HIV incidence in the intervention arms, this should 
not hamper our ability to detect differences in 3-year cumulative HIV incidence between 
the different trial arms.  
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Context 
In June 2013, WHO released new guidelines on the use of antiretroviral therapy (ART) 
for treating and preventing HIV infection [1]. Based on recent evidence that early ART 
initiation helps infected individuals to live a longer and healthier life and prevents 
transmission of the virus to others, WHO recommends broadening the spectrum of 
individuals eligible for ART. The new guidelines recommend initiating treatment in  
 HIV+ adults with CD4<500 cells/mm3,  
 HIV+ individuals in a serodiscordant couple, 
 HIV+ individuals with active TB or hepatitis B, 
 HIV+ pregnant and breastfeeding women, 
 HIV+ children under 5 years of age. 
 
The adoption by Zambia and South Africa of these new WHO guidelines is going to affect 
the HPTN-071 (popART) trial, in which individuals in arm C (standard of care) and B 
(universal testing but treatment according to national guidelines) are treated according 
to the national guidelines. Broadening the spectrum of eligible individuals is likely to 
increase the relative difference in 3-year cumulative incidence between arms B and C 
but to decrease the relative difference between arms A and B. The aim of this document 
is to use mathematical modeling to project the impact of the trial on 3-year cumulative 
incidence under different scenarios of adoption of the new guidelines in the two 
countries.  
Methods 
The basic model is the one described in [2]. Here we consider 5 variations of this model 
to account for different scenarios of adoption of the new WHO guidelines in country, 
which vary in terms of time of adoption and proportion of the population affected by the 
new guidelines. The scenarios considered are summarized in Table 1, and described in 
more detail in appendix 1.  
 
Table 1: Scenarios considered 
 
Original paper  Trial starts on 1st July 2013 
 National guidelines don’t change 
(see [2]) 
No changes in 
guidelines 
 Trial starts on 1st November 2013 
 National guidelines don’t change 
Late adoption – 
small eligibility 
 Trial starts on 1st November 2013 
 National guidelines change on 1st January 2015 
 40 % of pregnant women attend antenatal clinic and undertake 
HIV testing and linkage to care 
 5% of the HIV+ individuals with CD4>500 are in a serodiscordant 
couple or co-infected with TB or Hepatitis B 
Late adoption – 
large eligibility 
 Trial starts on 1st November 2013 
 National guidelines change on 1st January 2015 
 90 % of pregnant women attend antenatal clinic and undertake 
HIV testing and linkage to care 
 30% of the HIV+ individuals with CD4>500 are in a 
serodiscordant couple or co-infected with TB or Hepatitis B 
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Early adoption – 
small eligibility 
 Trial starts on 1st November 2013 
 National guidelines change on 1st January 2014 
 40 % of pregnant women attend antenatal clinic and undertake 
HIV testing and linkage to care 
 5% of the HIV+ individuals with CD4>500 are in a serodiscordant 
couple or co-infected with TB or Hepatitis B 
Early adoption – 
large eligibility 
 Trial starts on 1st November 2013 
 National guidelines change on 1st January 2014 
 90 % of pregnant women attend antenatal clinic and undertake 
HIV testing and linkage to care 
 30% of the HIV+ individuals with CD4>500 are in a 
serodiscordant couple or co-infected with TB or Hepatitis B 
Results 
Here we briefly present the predicted HIV incidence in arm C as well as incidence 
reduction in arms A and B under the 5 scenarios considered regarding adoption of WHO 
guidelines in country. 
Table 2 presents results for 3-year cumulative incidence.  
Figures 1 to 6 present the dynamic of prevalence and incidence over time (equivalent of 
Figure 3 in [2]).  
Figures 7 to 12 show the relative reduction in 3-year cumulative HIV incidence in arms 
A and B when parameters relating to the uptake of the interventions are varied (Figure 
4 in [2]).  
Figures 13 to 18 show the relative reduction in HIV incidence in arms A and B under 10 
parameter sets calibrated to the UNAIDS prevalence estimates (Figure S6 in [2]).  
 
As expected, the adoption of WHO guidelines in country increases the difference in 
predicted HIV incidence between arms B and C, and decreases that between arms A and 
C. Under the central target, the relative reduction in 3-year cumulative incidence in arm 
A ranged from 61% to 56% in Zambia and 62% to 58% in South Africa, depending on 
assumptions about the time of adoption and expected impact of the new guidelines (see 
Table 2). In arm B, it ranged from 25% to 37% in Zambia and 26% to 39% in South Africa 
(see Table 2). The adoption of the new guidelines would therefore increase our power 
to detect a difference between arms B and C. Moreover, in all scenarios considered, the 
power of detecting a difference between arms A and C, although reduced by the adoption 
of the new guidelines, was above 99%.  The adoption of the new guidelines would 
decrease our power to detect differences between arms A and B, but under the most 
extreme scenario (early adoption of the new guidelines and large eligibility), we 
estimated that the power for detecting a difference between arms A and B would remain 
above 60% (see the HPTN071-PopART protocol and appendix 2 for detail on power 
calculations). In this scenario, the power of detecting a difference between arms B and C 
would increase to at least 75%.  
 
Interestingly, the variability in the predicted reduction in HIV incidence in the 
intervention arms associated with uncertainty in the trial uptake and potential changes 
in behaviors at the community level was much larger than that associated with 
uncertainty in the date of adoption and impact of the new guidelines in country.  
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Table 1: Projected impact of the intervention on HIV incidence in Arms A and B 
compared with Arm C for central target under different scenarios regarding the 
adoption of WHO guidelines.  
 
Scenario Zambia South Africa  
Relative reduction in 3-
year cumulative incidence 
Mean 
annual 
incidence 
rate in 
arm C over 
3 years 
Relative reduction in 3-
year cumulative 
incidence 
Mean 
annual 
incidence 
rate in arm 
C over 3 
years 
Arm A Arm B Arm A Arm B 
Original paper 
(no change in  
guidelines, trial 
starts 1st July) 
61% 25% 1.86% 63% 27% 1.37% 
No change in 
guidelines, trial 
starts 1st 
November) 
61% 25% 1.85% 62% 26% 1.36% 
Late adoption of 
guidelines, small 
eligibility (see 
main text) 
59% 31% 1.75% 61% 32% 1. 32% 
Late adoption of 
guidelines, large 
eligibility (see 
main text) 
58% 32% 1.68% 60% 33% 1.28% 
Early adoption 
of guidelines, 
small eligibility 
(see main text) 
58% 35% 1.67% 60% 37% 1.28% 
Early adoption 
of guidelines, 
large eligibility 
(see main text) 
56% 37% 1.53% 58% 39% 1.20% 
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Figure 1-6: Model fit and projections under central target scenario for Zambia (top 
row) and South Africa (bottom row). Left panels show HIV prevalence and right panels 
show annualized HIV incidence over time. The red, blue and black lines correspond to 
arms A, B and C respectively. The grey dots and error bars are the UNAIDS HIV 
prevalence estimates. 
 
Figure 1: Original paper (no change in guidelines, trial starts 1st July 2013)  
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Figure 2: No change in guidelines, trial starts on 1st November 2013 
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Figure 3: Late adoption of guidelines, small eligibility (see main text) 
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Figure 4: Late adoption of guidelines, large eligibility (see main text) 
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Figure 5: Early adoption of guidelines, small eligibility (see main text) 
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Figure 6: Early adoption of guidelines, large eligibility (see main text) 
 
 
  
11 
 
Figure 7-12: Uncertainty on the trial outcome in Zambia (top panels) and South Africa 
(bottom panels). The red and blue histograms show the relative reduction in 3-year 
cumulative incidence in arms A and B respectively when parameters vary within ranges 
shown in the attached manuscript (Table 2). The left panels show results obtained when 
all parameters are varied, and the right panels when assuming no population-level 
behavioural changes associated with the intervention. 
 
Figure 7: Original paper (no change in guidelines, trial starts 1st July 2013)  
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Figure 8: No change in guidelines, trial starts on 1st November 2013 
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Figure 9: Late adoption of guidelines, small eligibility (see main text) 
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Figure 10: Late adoption of guidelines, large eligibility (see main text) 
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Figure 11: Early adoption of guidelines, small eligibility (see main text) 
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Figure 12: Early adoption of guidelines, large eligibility (see main text) 
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Figures 13-18: Projected impact of the intervention on HIV incidence in Arms A 
and B compared with Arm C for central target scenario in Zambia (top row) and 
South Africa (bottom row), under 10 parameter sets calibrated to the UNAIDS 
prevalence estimates.  The red dots show the best fit parameter set. 
 
Figure 13: Original paper (no change in guidelines, trial starts 1st July 2013)  
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Figure 14: No change in guidelines, trial starts on 1st November 2013 
 
 
 
 
Figure 15: Late adoption of guidelines, small eligibility (see main text) 
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Figure 16: Late adoption of guidelines, large eligibility (see main text) 
 
 
 
Figure 17: Early adoption of guidelines, small eligibility (see main text) 
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Figure 18: Early adoption of guidelines, large eligibility (see main text) 
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Discussion 
We used a modified model to project the impact on the HPTN-071 (popART) trial of the 
adoption of the new WHO guidelines on ART in Zambia and South Africa.  
This model does not account for individuals in pre-ART care who already know their HIV 
status and could initiate treatment very soon after adoption of the new guidelines, and 
therefore tends to underestimate the number of individuals who will initiate treatment 
just after adoption of the new guidelines (this effect could be studied in a future version 
of the model).  
The model also does not account for possible disruptions in the logistics of the health 
care facilities associated with the increase in number of eligible individuals, which tends 
to counterbalance the former effect.  
The anticipated date of guidelines adoption in country as well as the assumptions we 
have made about serodiscordant couples, co-infected individuals and pregnant women 
have a large impact on the predicted relative reduction in incidence between arms, 
however not as large as the impact of the uncertainty in parameters related to the 
intervention uptake and the potential behavioral changes at the community level.  
Our initial model was designed following the 2010 WHO guidelines for ART initiation. 
The extended model we presented here assumed that the national guidelines would 
abruptly change from these 2010 WHO guidelines to the 2013 ones. In practice, 
intermediate guidelines might be implemented in-between, for instance the option B+ 
which has already been adopted in Zambia and South Africa, although not yet 
implemented. Although our model does not incorporate such features, the scenarios we 
have explored cover the most extreme assumptions regarding adoption of the new WHO 
guidelines, and hence the range of power calculations we present should cover these 
intermediate scenarios. 
Finally, we have assumed that the trial would start on the 1st of November 2013. 
Sensitivity analyses (not presented here) showed that, as expected, the sooner the trial 
starts, the closer predictions are to our initial ones. 
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Appendix 1: description of the extended model incorporating adoption of new 
WHO guidelines in country 
In this document we only describe modifications to the model.  
 
We assume that each country adopts the new guidelines at a date . Before that date, 
the model is the same as the initial model [2], but with an updated date of start for the 
trial, assumed to be the 1st November 2013  
 
 HIV+ adults with CD4<500 cells/mm3 
After the date , we model, in all arms, an additional rate of testing and linking to care 
for individuals with CD4 350-500, which is equal to the background rate of testing and 
linking to care of individuals with CD4 200-350: with the notations of [2], 
. This reflects the fact that individuals with CD4 
350-500 were previously not eligible for ART initiation but become so when the 
countries adopt the new WHO guidelines.  
 
 HIV+ individuals in a serodiscordant couple or with active TB / hepatitis B 
 
Our model does not explicitly represent HIV+ individuals in a serodiscordant couple or 
coinfected with hepatitis B or active TB (SD-coinfected). If these individuals have 
CD4<500, they are already modeled as eligible for treatment, but not if they have 
CD4>500. To account for those, we assumed that HIV+ individuals in a serodiscordant 
couple or coinfected with hepatitis B or active TB represented a proportion  of 
all the HIV+ individuals with CD4>500. Moreover, we assumed that they get tested and 
linked to care at the same rate as HIV+ individuals with CD4 200-500, i.e. 
. At total, we approximated the 
testing and linkage to care of SD-coinfected individuals by an additional rate of testing 
and linkage to care  
applied to all HIV+ individuals with CD4>500. This approximation should be reliable for 
short-term predictions, and therefore suitable for predicting trial outcomes over 3 years.  
The proportion of HIV+ individuals with CD4>500 who are in a serodiscordant couple or 
have active TB or hepatitis B is difficult to estimate. Guided by data on serodiscordant 
couples in several sub-Saharan African countries [3], we have assumed two scenarios, 
where   (“small eligibility scenario”) and  (“large eligibility 
scenario”), where respectively 5 and 30% of the HIV+ individuals with CD4>500 are 
eligible as being SD-coinfected. 
 
 HIV+ pregnant and breastfeeding women 
 
Similarly, HIV+ pregnant or breastfeeding women (PBw) are not explicitly represented 
in our model. If they have CD4<500, they are already modeled as eligible for treatment. 
To account for those who have CD4>500, we assumed that adult HIV+ women get 
pregnant at a rate , where  is the annual per-capita birth 
rate,  is the proportion of adults in the population, 0.5 is roughly the proportion of women in the 
tadopt
tadopt
t test+,background
2 t( ) =1{t>tadopt }t test+,background
3 t( )
pSD-coinf
t test+,background
SD-coinf t( ) = t test+,background
2 t( ) = 1{t>tadopt }t test+,background
3 t( )
t test+,background
0 t( ) = pSD-coinft test+,background
SD-coinf t( ) =1{t>tadopt } pSD-coinft test+,background
3 t( )
pSD-coinf = 0.05 pSD-coinf = 0.30
wPBw t( ) = - log 1-
b0 t( )
0.5k
æ
èç
ö
ø÷
b0 t( )
k
23 
 
population, and hence  is the annual per adult woman birth rate (see [2] for sources for 
 and ). We further assumed that the uptake of HIV testing at antenatal clinics and 
subsequent linkage to care for these women is . At total, we approximated the 
testing and linkage to care of pregnant and breastfeeding women by an additional rate 
of testing and linkage to care  applied to all 
HIV+ women with CD4>500. This approximation should be very reliable for short-term 
predictions, and therefore suitable for predicting trial outcomes over 3 years.  
The uptake of HIV testing in antenatal clinics in sub-Saharan Africa is very 
heterogeneous, and rapidly improving [4].  Guided by data on several sub-Saharan 
African countries [4], we have assumed two scenarios, where   (“small 
eligibility scenario”) and  (“large eligibility scenario”), where respectively 40 
and 90% of pregnant women attend antenatal clinic and undertake HIV testing and 
linkage to care.  
 
 HIV+ children under 5 years of age 
 
Our model does not incorporate children so we do not model this component of the new 
guideline.   
 
 Date of adoption of the new WHO guidelines in country 
 
We assumed two main scenarios, where the countries would adopt the new WHO 
guidelines on 1st January 2014 (early adoption) or 1st January 2015 (late adoption).  
 
 Uncertainty analysis 
On top of uncertainty regarding the date of adoption of the new WHO guidelines in 
countries, as well as regarding the number of individuals affected by these new 
guidelines, several other sources of uncertainty might affect the predicted HIV incidence 
in each arm over the 3 years of the trial. First, as demonstrated in [2], several sets of 
parameters give relatively good fits to pre-trial estimates of national HIV prevalence by 
UNAIDS. Second, there is large uncertainty on what will be the uptake of the PopART 
intervention in arms A and B.  
To explore the extent to which those sources of uncertainty influence the power of the 
trial under the new WHO guidelines, we ran the model under several parameter sets that 
fitted the pre-trial national HIV prevalence estimates by UNAIDS (see [2] for the 
parameter sets used). Moreover, for the best fitting parameter set, we explored a range 
of values for parameters relating to the intervention uptake (see [2] for more detail).  
  
b0 t( )
0.5k
b0 t( ) k
ptest
PBw
t test+,background
PBw t( ) = -1{t>tadopt } log 1-
b0 t( )
0.5k
æ
èç
ö
ø÷
ptest
PBw
ptest
PBw = 0.40
ptest
PBw = 0.90
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Appendix 2: power calculations 
 
Power calculations were performed as described in the HPTN071-PopART protocol. 
Table 3 below presents additional power calculations for scenarios where the difference 
in HIV incidence between arms A and B is less marked (see Table 7 in protocol for other 
scenarios).  
 
Table 3: Power for comparison of HIV incidence between Arms A and B, with 7 
communities per arm and Population Cohort of 2500 adults per community (assuming 
that on average 2125 (85%) will be HIV-uninfected at baseline and that loss to follow-up 
will be 20% after 2 years and 25% after 3 years) 
HIV incidence rate/ 
100py (control arm) 
Between-cluster 
coefficient of 
variation (k) 
Effectiveness (%) 
Arm A 
Effectiveness (%) 
Arm B Power (%) 
1.00% 0.15 55% 35% 66% 
1.00% 0.15 55% 40% 46% 
1.00% 0.15 60% 35% 87% 
1.00% 0.15 60% 40% 72% 
     
1.00% 0.2 55% 35% 55% 
1.00% 0.2 55% 40% 37% 
1.00% 0.2 60% 35% 76% 
1.00% 0.2 60% 40% 61% 
     
1.50% 0.15 55% 35% 76% 
1.50% 0.15 55% 40% 55% 
1.50% 0.15 60% 35% 93% 
1.50% 0.15 60% 40% 82% 
     
1.50% 0.2 55% 35% 62% 
1.50% 0.2 55% 40% 42% 
1.50% 0.2 60% 35% 83% 
1.50% 0.2 60% 40% 68% 
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The following is a copy of the manuscript submitted for publication to PLoS One, which 
describes the initial model developed to assist the HPTN071-PopART trial.  
 
